ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
19.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026Trial
- Relationship between [European journal of nuclear medicine and molecular imaging · 2026Trial
- Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial.La Radiologia medica · 2026Trial
- Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.European urology open science · 2026Article
- Automated lesion tracking and treatment response classification on [European journal of nuclear medicine and molecular imaging · 2026Article
- Artificial Intelligence Across the Cancer Theranostics Workflow: Critical Appraisal of Current Evidence and Future Clinical Translation.Molecular imaging and biology · 2026Review
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- PSMA-PET response under [European journal of nuclear medicine and molecular imaging · 2026Article
- Can chatGPT-4o reliably standardize PSMA PET/CT and PET/MRI reports using PROMISE V2 criteria? - An exploratory study.EJNMMI research · 2026Article
- Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.Abdominal radiology (New York) · 2026Review
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.The Prostate · 2026Article
- Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer.Prostate cancer and prostatic diseases · 2026Review
- Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy.Nuclear medicine and molecular imaging · 2026Review
- Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [European journal of nuclear medicine and molecular imaging · 2026Article
- Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.JMIR research protocols · 2026Article
- Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.JCO precision oncology · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum.2023
Authors and funding
16 authors at 4 institutions in 2 countries.
Andrei GafitaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; agafita@mednet.ucla.edu.
Isabel RauscherDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Manuel WeberDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Boris HadaschikDepartment of Urology, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Hui WangDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Robert TauberDepartment of Urology, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Tristan R GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California; and.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Matthew B RettigDepartment of Urology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wolfgang A WeberDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Matthias R BenzAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Matthias EiberDepartment of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
Klinikum rechts der Isar · DEUniversity of California, Los Angeles · USDeutschen Konsortium für Translationale Krebsforschung · DEUniversity of Duisburg-Essen · DE
Funding
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MNCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015
Abstract
Our objective was to develop version 1.0 of a novel framework for response evaluation criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite response classification that combines responses by prostate-specific antigen (PSA) measurements and by RECIP 1.0 (PSA + RECIP).
Indexed as
Positron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadiopharmaceuticalsRetrospective StudiesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenRadiopharmaceuticals177Lu-PSMAinterim PETmetastatic castration-resistant prostate cancerPSMA PETradionuclide treatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06798558ClinicalTrials.gov
NCT06828263ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.